Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.
about
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialHow do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experimentThe prognostic profile of subfertile couples and treatment outcome after expectant management, intrauterine insemination and in vitro fertilisation: a study protocol for the meta-analysis of individual patient dataThe impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisRespective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaTranslating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer AssayBreast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.Measuring the performance of markers for guiding treatment decisionsUS Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatmentReview of the clinical studies using the 21-gene assay.The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS.Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting.Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidenceUnderstanding how breast cancer patients use risk information from genomic tests.Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Editorial: gene expression profile assays as an aid in treatment decision making in early-stage breast cancer.Oncotype dx results in multiple primary breast cancers.Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care.Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results.Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients.Patients' perceptions of gene expression profiling in breast cancer treatment decisions.Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.The application of Oncotype DX in early-stage lymph-node-positive disease.
P2860
Q24597456-290C1135-1AD9-4336-AFDD-EB2CF5968D0EQ24658523-2DB4DA20-6E7B-499E-B152-83DA95112AEAQ26825825-12C426BB-3C75-41CE-889B-479C19DC7FE6Q26861418-A4D58885-88A5-4965-B78A-F039B1B9E855Q28730529-312B9E29-FEC8-4111-80F0-74D350EE0713Q30497815-BFC04ADB-08FB-4B76-A565-DE707979F3B9Q33915023-8B663772-AC3D-495A-87F9-078F297BE7E7Q33966102-9C85C0C6-6A5F-412E-9A78-8E40DBB75332Q34114888-45DF1A6F-E233-4119-AAC0-1A585D9EEF96Q34338152-3AF4C1EE-C3D1-4543-9F39-355C55DB71ACQ34341066-51F9D77B-9338-425C-A826-EEEF41E2D92EQ34431985-3B8740CC-B5C9-4C03-AE6A-3860CC2AD56EQ34638067-985115A0-460A-4DEA-A194-9191086EAEA8Q34897226-F4458361-D683-4D87-AA96-D3D67E5089D4Q34974208-C34D01E7-CD8F-44BB-BDA3-481ADEE2B2F8Q35146930-A1027006-F54C-475B-A33C-F77398B14AA0Q35345599-BC5218F3-ADE3-4974-AB61-72B759A3623CQ35584053-2261F23E-6F57-4CE0-AF67-386069A20804Q35599773-F3624741-0FE9-4823-9601-E56F13D4792DQ36055953-D090F33C-3DC9-49C3-933B-82B5FF511C45Q36147839-8BCB207C-B169-4EC0-A5EC-C3AC387EAF27Q36183761-7EC185D8-0F8D-499F-86C1-2F4CF77905BEQ36253744-BA381282-ED5F-4BCB-9A6F-2C1044ED703AQ36339076-0CA1F5DF-BE65-4B2F-89D6-251CAD418D5FQ36424052-F611F420-5E48-41A7-96F2-65419D090B03Q36462893-BED37D73-D373-4B69-A01D-F5C8DD847309Q36503688-B4A2AD45-BB2A-48B9-ADF4-63DE43079364Q37008507-AFFB3A87-2332-47A9-9A94-E00AF6CE483AQ37095310-975CD849-98EB-4763-A4D2-0FC75DCC4C30Q37138266-21D00A1B-694D-46FE-9CA9-AA9BD2F65EDFQ37233796-F4222E4A-CAFC-4B9B-9A2F-7D4CDD56CBAEQ37476672-9BA346FD-C2A8-45FC-8EE1-F9ADF71C37FBQ37477742-12674F97-70A1-42F9-8998-488D2F96A775Q37585888-BDEB393E-41B7-4119-922C-988E47EB0F85Q37586558-616FDBEB-9B26-4A83-8279-09B51C3463C5Q37606937-393C6812-3582-44A6-878C-41D1159E2A32Q37719617-5602C697-6209-4B12-BF38-674961DBF5E8Q38024305-A48449CF-1DA6-45DC-897A-1169045CC803Q38081244-9335769E-6049-43D3-A0A9-30516E895A3CQ38180001-893EFDBE-EDF0-4A01-BC78-A55F4A039DB5
P2860
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of a commercial referen ...... in early-stage breast cancer.
@en
Impact of a commercial referen ...... in early-stage breast cancer.
@nl
type
label
Impact of a commercial referen ...... in early-stage breast cancer.
@en
Impact of a commercial referen ...... in early-stage breast cancer.
@nl
prefLabel
Impact of a commercial referen ...... in early-stage breast cancer.
@en
Impact of a commercial referen ...... in early-stage breast cancer.
@nl
P2093
P2860
P356
P1476
Impact of a commercial referen ...... in early-stage breast cancer.
@en
P2093
Allen L Cohn
Ruth Oratz
Scot M Sedlacek
P2860
P304
P356
10.1200/JOP.0742001
P407
P577
2007-07-01T00:00:00Z